AtriCure, Inc. (NASDAQ:ATRC) Shares Sold by Alliancebernstein L.P.

Alliancebernstein L.P. decreased its stake in shares of AtriCure, Inc. (NASDAQ:ATRC) by 3.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,835,449 shares of the medical device company’s stock after selling 136,999 shares during the period. Alliancebernstein L.P. owned approximately 7.87% of AtriCure worth $117,211,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Blue Trust Inc. boosted its stake in AtriCure by 1.8% during the fourth quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company’s stock valued at $414,000 after buying an additional 265 shares in the last quarter. Perkins Capital Management Inc. grew its stake in shares of AtriCure by 1.3% in the 4th quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company’s stock worth $927,000 after purchasing an additional 400 shares during the last quarter. Truist Financial Corp raised its holdings in shares of AtriCure by 2.6% in the 4th quarter. Truist Financial Corp now owns 15,717 shares of the medical device company’s stock worth $480,000 after purchasing an additional 403 shares in the last quarter. Franklin Resources Inc. lifted its stake in AtriCure by 0.9% during the third quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company’s stock valued at $1,569,000 after purchasing an additional 484 shares during the last quarter. Finally, LPL Financial LLC boosted its holdings in AtriCure by 5.4% during the fourth quarter. LPL Financial LLC now owns 11,465 shares of the medical device company’s stock worth $350,000 after buying an additional 584 shares in the last quarter. 99.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on ATRC shares. JMP Securities reiterated a “market outperform” rating and set a $60.00 price objective on shares of AtriCure in a research report on Monday, February 10th. JPMorgan Chase & Co. decreased their price target on AtriCure from $51.00 to $46.00 and set an “overweight” rating for the company in a research report on Thursday, March 27th. Piper Sandler boosted their price objective on AtriCure from $40.00 to $50.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Stifel Nicolaus raised their target price on shares of AtriCure from $36.00 to $48.00 and gave the stock a “buy” rating in a report on Thursday, February 13th. Finally, Oppenheimer lifted their target price on shares of AtriCure from $36.00 to $45.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $49.44.

Insider Transactions at AtriCure

In other AtriCure news, Director Karen Prange sold 6,100 shares of the business’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total value of $232,532.00. Following the transaction, the director now owns 17,828 shares in the company, valued at $679,603.36. The trade was a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 3.20% of the stock is currently owned by company insiders.

AtriCure Stock Performance

Shares of ATRC opened at $34.13 on Thursday. AtriCure, Inc. has a 52 week low of $18.94 and a 52 week high of $43.11. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. The company has a market capitalization of $1.67 billion, a PE ratio of -35.93 and a beta of 1.53. The company’s 50 day moving average price is $37.61 and its 200 day moving average price is $34.10.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.